HK1259294A1 - 用於治疗自身免疫疾病和癌症的组合物及方法 - Google Patents

用於治疗自身免疫疾病和癌症的组合物及方法

Info

Publication number
HK1259294A1
HK1259294A1 HK19101657.1A HK19101657A HK1259294A1 HK 1259294 A1 HK1259294 A1 HK 1259294A1 HK 19101657 A HK19101657 A HK 19101657A HK 1259294 A1 HK1259294 A1 HK 1259294A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
cancers
autoimmune diseases
treating autoimmune
Prior art date
Application number
HK19101657.1A
Other languages
English (en)
Chinese (zh)
Inventor
陈列平
陳列平
王俊
孙静玮
孫靜瑋
Original Assignee
耶鲁大学
耶魯大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 耶鲁大学, 耶魯大學 filed Critical 耶鲁大学
Publication of HK1259294A1 publication Critical patent/HK1259294A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
HK19101657.1A 2015-11-10 2016-11-09 用於治疗自身免疫疾病和癌症的组合物及方法 HK1259294A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253437P 2015-11-10 2015-11-10
US62/253437 2015-11-10
PCT/US2016/061086 WO2017083354A1 (en) 2015-11-10 2016-11-09 Compositions and methods for treating autoimmune diseases and cancers

Publications (1)

Publication Number Publication Date
HK1259294A1 true HK1259294A1 (zh) 2019-11-29

Family

ID=58695157

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101657.1A HK1259294A1 (zh) 2015-11-10 2016-11-09 用於治疗自身免疫疾病和癌症的组合物及方法

Country Status (13)

Country Link
US (2) US20180318419A1 (enExample)
EP (2) EP4512827A3 (enExample)
JP (4) JP6924495B2 (enExample)
KR (1) KR102810368B1 (enExample)
CN (2) CN116510015A (enExample)
AU (2) AU2016354100B2 (enExample)
BR (1) BR112018009361A8 (enExample)
CA (1) CA3002095A1 (enExample)
HK (1) HK1259294A1 (enExample)
MX (2) MX2018005830A (enExample)
RU (1) RU2761980C2 (enExample)
TW (2) TW202330019A (enExample)
WO (1) WO2017083354A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP7069177B2 (ja) 2016-09-21 2022-05-17 ネクストキュア インコーポレイテッド シグレック－１５に対する抗体及びその使用方法
CN113138273B (zh) * 2020-01-17 2024-06-18 孟民杰 一种应用于肺癌快速筛查及免疫靶向治疗检测的试剂盒及其用途
JP7364315B2 (ja) * 2020-03-27 2023-10-18 ビオシオン インコーポレイテッド 抗体結合Ｓｉｇｌｅｃ１５及びその使用
CN113817057B (zh) * 2020-06-19 2024-02-20 盛禾(中国)生物制药有限公司 一种抗siglec15抗体及其应用
CN114525256A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
CA3204359A1 (en) * 2020-12-08 2022-06-16 Guizhou Sinorda Biotechnology Co. Ltd. Modified t cells for adoptive immunotherapy
CN114657132A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15靶向抑制因子的多能干细胞及其衍生物与应用
ES2955819T3 (es) * 2021-01-21 2023-12-07 Guizhou Sinorda Biotechnology Co Ltd Linfocitos T modificados para inmunoterapia adoptiva
EP4299591A4 (en) * 2021-02-23 2025-03-12 Shanghai Jemincare Pharmaceuticals Co., Ltd. Production of Siglec-15 binding protein and use thereof
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
WO2022188871A1 (en) * 2021-03-12 2022-09-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric siglec15
CN116983412A (zh) * 2023-08-04 2023-11-03 南通大学 Siglec-15-SE超增强子在制备治疗肿瘤的产品中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
AU731044B2 (en) * 1995-06-27 2001-03-22 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
IL162077A0 (en) * 2001-11-21 2005-11-20 Univ Leland Stanford Junior Polynucleotide therapy the board of trustees of the leland stanford junior university
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP2056865B1 (en) * 2006-08-28 2013-12-25 Omnio Healer AB Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
EP2907826B1 (en) * 2007-10-11 2018-05-30 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
US8575316B2 (en) 2009-04-09 2013-11-05 Daiichi Sankyo Company, Limited Anti-Siglec-15 antibody
GEP201706660B (en) * 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN103328005A (zh) * 2010-08-13 2013-09-25 贝勒研究院 基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂
US9114131B2 (en) * 2010-10-05 2015-08-25 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein Siglec-15
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
EP2753356B1 (en) * 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
EP2610263A1 (de) * 2011-12-30 2013-07-03 Brossmer, Reinhard Sialinsäure-Dimere
US20160264684A1 (en) * 2013-10-10 2016-09-15 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX384991B (es) * 2014-03-19 2025-03-14 Genzyme Corp Glucomodificación de restos de direccionamiento específica del sitio.

Also Published As

Publication number Publication date
EP3373962A4 (en) 2020-02-19
RU2018121050A3 (enExample) 2020-03-13
CN116510015A (zh) 2023-08-01
AU2016354100A1 (en) 2018-06-21
JP2021167353A (ja) 2021-10-21
TWI847955B (zh) 2024-07-11
JP2025156500A (ja) 2025-10-14
MX2023012451A (es) 2023-10-31
US20180318419A1 (en) 2018-11-08
MX2018005830A (es) 2018-11-12
KR102810368B1 (ko) 2025-05-19
RU2761980C2 (ru) 2021-12-14
AU2024201282A1 (en) 2024-03-14
EP4512827A3 (en) 2025-04-30
CN108430498A (zh) 2018-08-21
KR20180073691A (ko) 2018-07-02
US20220168419A1 (en) 2022-06-02
JP2018533591A (ja) 2018-11-15
BR112018009361A8 (pt) 2019-02-26
TW201729841A (zh) 2017-09-01
RU2018121050A (ru) 2019-12-13
JP2023096078A (ja) 2023-07-06
WO2017083354A1 (en) 2017-05-18
JP6924495B2 (ja) 2021-08-25
BR112018009361A2 (en) 2018-11-13
AU2016354100B2 (en) 2023-11-30
CA3002095A1 (en) 2017-05-18
EP4512827A2 (en) 2025-02-26
EP3373962A1 (en) 2018-09-19
TW202330019A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
HK1259294A1 (zh) 用於治疗自身免疫疾病和癌症的组合物及方法
HK1259079A1 (zh) 与免疫适应症的多模式治疗性细胞体系有关的组合物和方法
ZA201708265B (en) Tigit-binding agents and uses thereof
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2016055432A3 (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
WO2017030823A3 (en) Anti-tigit antibodies
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
WO2015116868A3 (en) Molecular profiling of immune modulators
WO2016077639A3 (en) Nanovesicular therapies
WO2015049365A3 (en) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
HK1255056A1 (zh) 抗cd115抗体
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
WO2015175884A3 (en) Compositions and methods for treating and preventing pancreatitis, renal injury and cancer
WO2015134603A3 (en) Methods for treating cancer
WO2016086022A3 (en) Heteroaromatic imidazolyl compounds and methods for treating cancer
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
HK40098354A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2，3-二氢哒嗪-4-甲酰胺
HK40097687B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
WO2015200699A3 (en) Macrocyclic compounds and methods of treatment